{"gene":"TIMP3","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2005,"finding":"TIMP3 directly inhibits TACE (ADAM17), the TNF-alpha-converting enzyme. In insulin receptor heterozygous (Insr+/-) mice, TIMP3 deficiency led to unchecked TACE activity, increased soluble TNF-alpha, and subsequent diabetes and vascular inflammation. Pharmacological TACE inhibition reduced hyperglycemia, and Tace+/- mice showed increased insulin sensitivity, placing TIMP3 upstream of TACE-mediated TNF-alpha shedding in a metabolic/inflammatory pathway.","method":"Genetic mouse models (Insr+/-, Timp3+/-, double heterozygotes), TACE activity assays, TNF-alpha measurement, pharmacological TACE inhibition","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models, pharmacological rescue, and epistasis in vivo; replicated across multiple experimental conditions in one rigorous study","pmids":["16294222"],"is_preprint":false},{"year":2012,"finding":"TACE (ADAM17) exists predominantly as dimers at the cell surface under basal conditions; dimerization requires its cytoplasmic domain and enables efficient association with TIMP3, which silences TACE activity. Upon ERK or p38 MAPK activation, the dimer-to-monomer shift decreases TIMP3 association and increases TACE-mediated ectodomain shedding of TGF-alpha, establishing TIMP3 as a dimer-dependent inhibitor of TACE.","method":"Cell-surface TACE dimerization assays, co-immunoprecipitation of TIMP3 with TACE, MAPK pathway activation/inhibition, TGF-alpha shedding assays, cytoplasmic domain mutagenesis","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mechanistic dissection using mutagenesis, co-IP, and functional shedding assays in one rigorous study","pmids":["22550340"],"is_preprint":false},{"year":2007,"finding":"TIMP3 inhibits alpha-secretase cleavage of amyloid precursor protein (APP) and ApoER2 by blocking ADAM-10 and ADAM-17. TIMP3 decreased surface levels of ADAM-10, APP, and ApoER2, increased APP beta-CTF and Abeta production, and directed APP toward endocytosis and beta-secretase cleavage rather than alpha-secretase cleavage.","method":"Recombinant TIMP3 treatment, ADAM-10/17 activity assays, Western blot for APP processing fragments, surface biotinylation, cell transfection in neuroblastoma/glia/COS7 cells","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (surface labeling, fragment analysis, activity assay) in single lab","pmids":["17913923"],"is_preprint":false},{"year":2009,"finding":"TIMP3 deficiency in mice leads to accelerated TACE activity and elevated soluble TNF-alpha after ureteral obstruction, followed by enhanced MMP2 (but not MMP9) activation, increased fibrosis, and apoptosis. Additional deletion of TNF-alpha in TIMP3-/- mice markedly reduced inflammation and MMP induction, placing TIMP3 upstream of TACE-TNF-alpha-MMP signaling in renal injury.","method":"Genetic knockout mice (TIMP3-/-, TIMP3-/-/TNFalpha-/-), unilateral ureteral obstruction model, TACE activity assay, MMP zymography, histopathology, MMP inhibitor treatment","journal":"Journal of the American Society of Nephrology : JASN","confidence":"High","confidence_rationale":"Tier 2 / Strong — double-knockout epistasis, pharmacological inhibition, and multiple orthogonal biochemical readouts","pmids":["19406980"],"is_preprint":false},{"year":2012,"finding":"TIMP3 stabilizes capillary tube networks and inhibits metalloproteolytic activity and angiogenic signaling in endothelial cells; this function is lost when pericytes transition to myofibroblasts. Pericyte-derived TIMP3 (in contrast to ADAMTS1) maintains microvascular stability, and Timp3-/- mice have spontaneous microvascular rarefaction and exaggerated fibrotic response to injury.","method":"3D capillary tube assays, Timp3-/- mice, in vivo kidney injury models, pericyte-myofibroblast differentiation assays, metalloproteolytic activity assays","journal":"Journal of the American Society of Nephrology : JASN","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro 3D assay, genetic knockout, and in vivo injury model with mechanistic readouts","pmids":["22383695"],"is_preprint":false},{"year":2012,"finding":"Loss of TIMP3 in the Akita diabetic mouse background selectively exacerbates diabetic renal injury (albuminuria, mesangial expansion, kidney hypertrophy) with elevated TACE activity, increased reactive oxygen species, NADPH oxidase activity, and PKCbeta1 elevation; cardiac function was unaffected, demonstrating a kidney-selective protective role of TIMP3 in diabetes.","method":"Double-mutant mice (TIMP3-/-/Akita), albuminuria measurement, TACE activity assay, ROS/NADPH oxidase assays, Western blot for PKC isoforms and signaling molecules","journal":"American journal of physiology. Renal physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — organ-specific genetic epistasis with multiple mechanistic pathway analyses","pmids":["22896043"],"is_preprint":false},{"year":2012,"finding":"Timp3 deficiency in Ang II-infused mice causes abdominal aortic aneurysm (AAA) with reduced collagen and elastin proteins (not mRNA), elevated MMP2 and broad proteolytic activities. Additional deletion of Mmp2 exacerbated AAA and rupture; bone marrow reconstitution with WT cells in Timp3-/-/Mmp2-/- mice reduced inflammation and prevented AAA, identifying an MMP-dependent and bone marrow inflammatory component downstream of TIMP3.","method":"Timp3-/- mice, Ang II infusion, Mmp2-/- double knockout, bone marrow transplantation, MMP inhibitor (PD166793) treatment, zymography, protein/mRNA analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models, pharmacological inhibition, and bone marrow chimera rescue in one comprehensive study","pmids":["23144462"],"is_preprint":false},{"year":2013,"finding":"TIMP3 deficiency in diabetic mice leads to reduced FoxO1 expression and its autophagy-related targets, with increased STAT1. Re-expression of TIMP3 in Timp3-/- mesangial cells rescued FoxO1 and its targets and decreased STAT1, establishing a TIMP3 → STAT1 → FoxO1 pathway in diabetic kidney disease.","method":"Diabetic Timp3-/- mice, microarray profiling, TIMP3 re-expression in mesangial cells, qPCR/Western blot for FoxO1, STAT1 knockdown rescue experiments, human kidney biopsy validation","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model, in vitro rescue, STAT1 knockdown epistasis, and human tissue validation","pmids":["23401241"],"is_preprint":false},{"year":2013,"finding":"In renal injury after ureteral obstruction, TIMP3 deficiency (but not TIMP2 deficiency) increases MMP2 activation, TACE activity, caspase-3 activity, and fibrosis through collagen I/III, CTGF, TGF-beta/Smad2/3 pathway activation. TIMP2 deficiency blocks MMP2 activation and reduces fibrosis, demonstrating divergent and opposing roles: TIMP3 protects from damage while TIMP2 promotes injury through MMP2 activation.","method":"Timp2-/- and Timp3-/- mice, unilateral ureteral obstruction, gene microarray, zymography for MMP2 activation, TACE activity assay, caspase assay, histopathology","journal":"Kidney international","confidence":"High","confidence_rationale":"Tier 2 / Strong — comparative genetic knockouts with multiple orthogonal mechanistic readouts","pmids":["23760282"],"is_preprint":false},{"year":2014,"finding":"In Ang II-infused mice, TIMP3 deficiency produces excess fibrosis (without hypertrophy) involving post-translational stabilization and deposition of collagen by matricellular proteins osteopontin and SPARC, increased inflammation, and elevated TACE activity; this is distinct from TIMP2 deficiency effects and appears independent of canonical MMP-inhibitory function.","method":"TIMP2-/- and TIMP3-/- mice, Ang II infusion, adult cardiomyocyte/fibroblast co-culture, cyclic stretch assays, Western blot for osteopontin and SPARC, collagen quantification, TACE activity assay","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Strong — comparative genetic models, in vitro co-culture mechanistic follow-up, multiple orthogonal biochemical assays","pmids":["24692173"],"is_preprint":false},{"year":2007,"finding":"TIMP3 deficiency accelerates maladaptive cardiac remodeling after myocardial infarction, with greater left ventricular dilation, increased gelatinase MMP activity, elevated TNF-alpha levels, increased blood vessel density, cell proliferation, apoptosis in infarct area, and reduced collagen in remote myocardium, resulting in accelerated systolic dysfunction and higher mortality.","method":"Timp3-/- mice, coronary artery ligation, echocardiography, pressure-volume measurements, MMP zymography, histopathology, ELISA for TNF-alpha","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO model, multiple functional and biochemical readouts with temporal resolution","pmids":["17945252"],"is_preprint":false},{"year":2015,"finding":"TIMP3 promotes apoptosis in endothelial cells via a caspase-independent mechanism. The apoptotic activity is independent of MMP inhibitory activity and requires KDR (VEGFR2) expression. TIMP3 inhibits matrix-induced focal adhesion kinase (FAK) tyrosine phosphorylation, disrupts FAK association with paxillin, and prevents incorporation of beta3 integrin, FAK, and paxillin into focal adhesion contacts, an effect not reversed by caspase inhibitors.","method":"PAE/KDR vs PAE/beta-R cell lines, recombinant TIMP3 treatment, caspase inhibitor treatment, FAK phosphorylation assay, co-immunoprecipitation of FAK/paxillin, immunofluorescence of focal adhesions, in vivo tumor assay with TIMP3-overexpressing breast carcinoma cells","journal":"Apoptosis : an international journal on programmed cell death","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (co-IP, phosphorylation assay, pharmacological inhibition, receptor-specific cell lines) with mechanistic pathway dissection","pmids":["25558000"],"is_preprint":false},{"year":2016,"finding":"TIMP3 accumulation in CADASIL acts through inhibition of ADAM17 and HB-EGF to regulate cerebral arterial tone and blood flow responses. In CADASIL mice, exogenous ADAM17 or HB-EGF restored cerebrovascular responses. Upregulated voltage-dependent potassium channel (KV) number in cerebral arterial myocytes was identified as a downstream effector of TIMP3-induced cerebrovascular deficits.","method":"TgNotch3(R169C) CADASIL mouse model, TgBAC-TIMP3 overexpressing mice, Timp3 haploinsufficiency rescue, cerebral blood flow measurements, ex vivo arterial tone assays, patch-clamp for KV channels, ADAM17/HB-EGF exogenous treatment","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models, pharmacological rescue, electrophysiological measurements, and mechanistic pathway tracing in one study","pmids":["27476853"],"is_preprint":false},{"year":2016,"finding":"In CADASIL mice, elevated TIMP3 (but not Notch3 ECD deposition) impairs cerebral blood flow autoregulation and functional hyperemia. Haploinsufficiency of Timp3 rescues cerebrovascular reactivity deficits. A separate TgBAC-TIMP3 overexpressing mouse also displays attenuated myogenic responses of brain arteries, confirming TIMP3 level as a direct determinant of cerebrovascular function.","method":"TgNotch3(R169C) mice with Timp3 haploinsufficiency, TgBAC-TIMP3 transgenic mice, cerebral blood flow measurements (laser Doppler), ex vivo pressurized artery myogenic response assays","journal":"Annals of neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent transgenic/knockout models with direct functional vascular measurements","pmids":["26648042"],"is_preprint":false},{"year":2018,"finding":"Pericyte ALK5 (TGF-beta receptor) signaling upregulates TIMP3 expression; pericyte-specific ALK5 knockout in embryonic mice downregulates TIMP3, leading to germinal matrix hemorrhage with abnormal microvessel dilation, reduced pericyte coverage, EC hyperproliferation, and enhanced perivascular MMP activity. Exogenous TIMP3 administration to ALK5-mutant embryos improved endothelial morphogenesis and attenuated hemorrhage, placing TIMP3 downstream of pericyte ALK5 in brain vascular morphogenesis.","method":"Pericyte-specific Alk5 conditional knockout mice, TIMP3 protein administration in vivo, histopathology, MMP activity assays, quantification of vascular phenotypes","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional genetic KO, in vivo protein rescue, and multiple vascular readouts","pmids":["29456135"],"is_preprint":false},{"year":1997,"finding":"TIMP3 is expressed and secreted by retinal pigment epithelium (RPE), choroidal microcapillary endothelium, and pericytes. Unlike TIMP-1 and -2 (which are secreted into culture medium), TIMP3 localizes exclusively to the extracellular matrix and is not found in conditioned medium. In vivo, TIMP3 immunostaining is pronounced in Bruch's membrane, particularly near RPE and endothelial basement membranes.","method":"RT-PCR, Northern analysis, Western immunoblot of conditioned medium vs ECM fractions, immunohistochemistry of retina/choroid sections, cultured RPE/pericyte/endothelial cells","journal":"Current eye research","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct fractionation experiments (ECM vs. medium) with multiple cell types and in vivo IHC validation","pmids":["9068940"],"is_preprint":false},{"year":1995,"finding":"The human TIMP3 gene is TATA-less, initiates transcription at one major site, consists of five exons and four introns spanning ~30 kb, maps to chromosome 22q13.1, and gives rise to three distinct mRNAs via alternative polyadenylation. The first 112 bases of the promoter (containing multiple Sp1 sites) confer high basal expression; the region from -463 to -112 is a major determinant of serum inducibility, conferring cell cycle regulation.","method":"Genomic cloning and sequencing, somatic cell hybrid mapping, promoter-reporter deletion assays, serum stimulation of growth-arrested cells","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct promoter mapping with deletion reporter assays and chromosomal mapping","pmids":["7487894"],"is_preprint":false},{"year":2003,"finding":"The SFD-associated S156C mutation in TIMP3 does not affect MMP inhibitory activity or metalloproteinase homeostasis in fibroblasts derived from mutant mice. Instead, mutant TIMP3(S156C) accumulates in the ECM (not due to altered turnover rate) and this accumulation alters cellular morphology. Loss of TIMP3 function in determining cellular morphology (not protease inhibition) is proposed as the pathogenic mechanism.","method":"Immortalized fibroblasts from Timp3-/- and Timp3(S156C/S156C) mice, MMP activity assays, ECM fractionation, pulse-chase for turnover rates, phenotypic analysis","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — direct enzyme activity assays and ECM fractionation in defined genetic cell lines; single lab","pmids":["12942551"],"is_preprint":false},{"year":2008,"finding":"The S156C SFD mutation does not impair TIMP3's inhibitory activities toward TACE, ADAMTS4/5, aggrecan-cleaving MMPs, or its anti-angiogenic properties in fibrin bead assays. TIMP3 S156C blocks VEGF binding to VEGFR2 to the same extent as wild-type TIMP3. In contrast, Timp3-/- tissue shows significantly enhanced TACE activity (but not ADAMTS4/5 or MMP activity), suggesting compensatory inhibitors for the latter enzymes.","method":"Timp3 S156C knock-in and Timp3-/- mice, TACE/ADAMTS4/5/MMP activity assays from tissue extracts, fibrin bead angiogenesis assay, VEGF-VEGFR2 binding assay with recombinant proteins, rescue with recombinant TIMP3","journal":"Matrix biology : journal of the International Society for Matrix Biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with recombinant proteins, multiple enzyme activity assays, genetic models, functional angiogenesis assay in one study","pmids":["18295466"],"is_preprint":false},{"year":2012,"finding":"TIMP3 deficiency leads to spontaneous accumulation and activation of hepatic CD4+, CD8+, and NKT cells. In Con A-induced autoimmune hepatitis, Timp3-/- mice have a greatly enhanced Th1 cytokine response and acute liver failure that mechanistically depends on TNF signaling. Bone marrow chimera experiments established that hepatic stromal (not hematopoietic) TIMP3 provides protection, with hepatocytes identified as the major source of Timp3 in resting liver.","method":"Timp3-/- mice, Con A model, bone marrow chimeras, flow cytometry of liver lymphocyte populations, Tnf genetic crosses, in situ hybridization/immunostaining for cell-type-specific Timp3 expression","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 / Strong — bone marrow chimera epistasis, TNF genetic interaction, multiple cell-type characterization","pmids":["22323541"],"is_preprint":false},{"year":2011,"finding":"TIMP3 deficiency leads to TNF dysregulation, earlier caspase activation, accelerated mitochondrial apoptosis, faster loss of STAT3 and TGFbeta3, E-cadherin fragmentation, accelerated adipogenesis, and greater macrophage/T-cell infiltration during mammary gland involution. Crossing in Tnf deficiency abrogated caspase-3 activation but paradoxically heightened macrophage/T-cell influx, showing that TIMP3 differentially controls apoptosis (TNF-dependent) and inflammatory cell infiltration (TNF-independent) during involution.","method":"Timp3-/- and Timp3-/-/Tnf-/- mice, mammary gland involution model, caspase activity assays, Western blot for signaling molecules, flow cytometry/histopathology for immune cells","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — double-knockout epistasis dissecting TNF-dependent vs. independent pathways with multiple orthogonal readouts","pmids":["22053204"],"is_preprint":false},{"year":2014,"finding":"TIMP3 loss in ApoE-/- mice increases atherosclerosis with greater macrophage plaque infiltration, elevated serum MCP-1, and expansion of inflammatory (M1) Gr1+ macrophages in circulation and aortic tissue, establishing TIMP3 as a regulator of macrophage inflammatory polarization in atherosclerosis.","method":"ApoE-/-/Timp3-/- double-knockout mice, en face aorta analysis, aortic root histology, FACS for macrophage subsets, serum MCP-1 ELISA, metabolomics","journal":"Atherosclerosis","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model with multiple vascular and immunological readouts","pmids":["24943223"],"is_preprint":false},{"year":2014,"finding":"Genetic loss of Timp3 protects mice from carcinogen-induced hepatocellular carcinoma (HCC): all WT mice developed HCC by 12 months, while only 33% of Timp3-/- mice did. Protection occurs through precocious activation of p53, p38, and Notch pathways, leading to hepatocyte senescence rather than apoptosis; TNF signaling was dispensable for this protection.","method":"Timp3-/- mice, diethylnitrosamine carcinogen model, immunohistochemistry and Western blot for p53/p38/Notch, senescence assays (SA-beta-Gal), apoptosis assays, Timp3-/-/Tnf-/- epistasis, Timp3-/- mouse embryo fibroblasts","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic KO with pathway analysis, TNF epistasis, and in vitro corroboration","pmids":["25347747"],"is_preprint":false},{"year":2015,"finding":"In MMTV-PyMT and MMTV-Neu breast cancer models, Timp3 loss delays tumor onset and some mice remain tumor-free. The tumor-suppression in Timp3-null mice requires TNFR1 signaling. Transplantation experiments showed that Timp3 deficiency in the host stroma (not tumor cells) is sufficient to delay early but not advanced tumor growth.","method":"MMTV-PyMT/Timp3-/- and MMTV-Neu/Timp3-/- mice, Tnfr1 genetic crosses (epistasis), tumor cell transplantation into Timp3-/- hosts, tumor onset/incidence measurement","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic crosses, epistasis with TNFR1, and transplantation experiment identifying spatial requirement","pmids":["25807548"],"is_preprint":false},{"year":2017,"finding":"Hepatocyte-specific TIMP3 overexpression (AlbT3 mice) improved glucose metabolism, hepatic fatty acid oxidation, and cholesterol homeostasis during high-fat diet. This was linked to regulation of ADAM17: hepatocyte-specific Adam17 knockout (A17LKO, but not myeloid Adam17 KO) similarly improved liver steatosis, placing TIMP3 upstream of hepatocyte ADAM17 in NAFLD protection. Both AlbT3 and A17LKO mice showed reduced hepatic tumorigenesis.","method":"Hepatocyte-specific TIMP3 transgenic (AlbT3), hepatocyte-specific Adam17 KO (A17LKO), myeloid-specific Adam17 KO (A17MKO) mice, HFD model, diethylnitrosamine tumor model, metabolic phenotyping, gene expression analysis","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific transgenic and KO models with genetic epistasis between TIMP3 and ADAM17","pmids":["28751722"],"is_preprint":false},{"year":2018,"finding":"TIMP3 is a CLOCK-dependent diurnal gene in human keratinocytes: CLOCK knockdown reduces TIMP3 expression rhythmically, and TIMP3 inversely regulates MMP-1 and inflammatory cytokines (TNF-alpha, CXCL1, IL-8). UVB exposure downregulates both CLOCK and TIMP3, increasing TNF-alpha secretion and CXCL1/IL-8 transcription via C/EBP-alpha. TIMP3 overexpression decreases, and knockdown increases, UVB-induced TNF-alpha secretion.","method":"CLOCK knockdown in keratinocytes, TIMP3 KD/OE, UVB irradiation, MMP-1 activity assay, ELISA for TNF-alpha, qPCR/Western blot for cytokines, circadian rhythm monitoring","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple KD/OE experiments with functional cytokine readouts; single lab, in vitro","pmids":["29180440"],"is_preprint":false},{"year":2019,"finding":"Glycosaminoglycans (specifically sulfated hyaluronan and heparin) influence MMP2/TIMP3 complex formation and MMP2 inhibition. Sulfated hyaluronan supports fibrillar co-alignment of MMP2 and TIMP3, stabilizing interactions between MMP2 hemopexin domain and TIMP3 C-terminal tail. Molecular modeling indicates that GAG can either support or preclude TIMP3-mediated MMP2 inhibition depending on the sequential order of complex formation.","method":"In vitro MMP2 activity assays with bone marrow stromal cells, MMP2/TIMP3 complex formation assays, in silico docking and molecular dynamics simulations, immunofluorescence imaging of fibrillar structures","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro biochemical assay with structural modeling; single lab, no mutagenesis validation","pmids":["30894640"],"is_preprint":false},{"year":2016,"finding":"KDM1A (histone demethylase) promotes lung cancer metastasis by silencing TIMP3 through H3K4me2 demethylation at the TIMP3 promoter. KDM1A knockdown increases TIMP3, which in turn inhibits MMP2 expression and JNK phosphorylation. Restoring TIMP3 expression in KDM1A-deficient cells inhibits invasion/migration, and TIMP3 knockdown in KDM1A-deficient cells rescues metastatic capability.","method":"KDM1A KD/OE in NSCLC cells, ChIP-qPCR for H3K4me2 at TIMP3 promoter, TIMP3 KD rescue experiment, MMP2 activity assay, JNK phosphorylation assay, Transwell invasion assay, pharmacological inhibition","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for histone mark, epistasis rescue experiment, functional invasion assay; single lab","pmids":["27058897"],"is_preprint":false},{"year":2017,"finding":"Hepatocyte-specific TIMP3 overexpression or Adam17 deletion protected against iron overload-mediated cardiac dysfunction and liver injury. In Timp3-/- mice with iron overload, constituently lower ferroportin levels led to twofold higher hepatic iron accumulation, increased MMP-2 activation, and greater hepatic inflammatory cytokine and MMP-12/13 expression.","method":"Timp3-/- mice, chronic iron overload model, echocardiography, hepatic iron quantification, ferroportin Western blot, MMP zymography, gelatinase activity assay, histopathology","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO model with multiple mechanistic readouts; single lab","pmids":["29373036"],"is_preprint":false},{"year":2019,"finding":"HDAC9 promotes trophoblast cell migration and invasion by repressing TIMP3 transcription through promoter histone hypoacetylation. In preeclampsia, HDAC9 is downregulated in syncytiotrophoblasts; HDAC9 knockdown increases histone acetylation at the TIMP3 promoter (confirmed by ChIP-qPCR), elevates TIMP3 expression, and inhibits cell migration and invasion in HTR-8/SVneo cells.","method":"ChIP-qPCR for histone acetylation at TIMP3 promoter, HDAC9 siRNA knockdown and rescue, Transwell migration/invasion assays, RT-qPCR and Western blot, immunohistochemistry in human placentas","journal":"American journal of hypertension","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP evidence for histone acetylation at TIMP3 promoter with functional rescue; single lab","pmids":["30715128"],"is_preprint":false},{"year":2020,"finding":"ALKBH5 (an m6A RNA demethylase) represses TIMP3 mRNA stability and protein production in non-small cell lung cancer. RIP-Seq identified TIMP3 mRNA as an ALKBH5-bound target; ALKBH5 knockdown increased TIMP3 expression and reduced tumor growth in vivo, establishing an ALKBH5-mediated m6A modification as a post-transcriptional regulator of TIMP3.","method":"RNA immunoprecipitation sequencing (RIP-Seq), ALKBH5 KD/OE, mRNA stability assay, Western blot, in vivo xenograft, RT-qPCR","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — RIP-Seq identifies direct binding, mRNA stability assay provides mechanistic link; single lab","pmids":["31927006"],"is_preprint":false},{"year":2021,"finding":"LncRNA ROR recruits histone methyltransferase MLL1 to promote H3K4 trimethylation at the TIMP3 locus, enhancing TIMP3 transcription and breast cancer progression. RIP, RNA pull-down, and ChIP assays confirmed lncRNA ROR-MLL1-H3K4me3-TIMP3 axis; lncRNA ROR knockdown inhibited breast cancer cell invasion and tumor growth through downregulation of TIMP3.","method":"RIP assay, RNA pull-down, ChIP for H3K4me3 at TIMP3, lncRNA ROR KD/OE, Transwell invasion assay, in vivo xenograft","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct chromatin occupancy assay (ChIP) and RNA-protein interaction assays; single lab","pmids":["33653378"],"is_preprint":false}],"current_model":"TIMP3 is an ECM-bound inhibitor with a broad substrate spectrum including MMPs, ADAM17/TACE, ADAMs, and ADAMTSs; it maintains vascular, renal, cardiac, and hepatic homeostasis primarily by restricting TACE-mediated TNF-alpha shedding and MMP-dependent ECM degradation, and it promotes endothelial apoptosis through a caspase-independent FAK-disruption mechanism, while its expression level is regulated by the CLOCK circadian factor, by epigenetic writers/erasers (KDM1A, HDAC9, MLL1, ALKBH5), and by numerous miRNAs targeting its long 3′UTR."},"narrative":{"mechanistic_narrative":"TIMP3 is an extracellular-matrix-bound metalloproteinase inhibitor that maintains vascular, renal, cardiac, hepatic, and metabolic homeostasis primarily by restraining the sheddase ADAM17/TACE and matrix metalloproteinases [PMID:16294222, PMID:19406980, PMID:18295466]. Unlike other TIMPs, TIMP3 is sequestered exclusively in the ECM rather than secreted into the medium, accumulating in basement membranes near RPE and endothelial cells [PMID:9068940]. A central function is direct inhibition of TACE, silencing TNF-alpha shedding: TACE exists as cell-surface dimers whose cytoplasmic-domain-dependent dimerization enables stable TIMP3 association, and MAPK-driven dimer-to-monomer conversion releases TIMP3 to permit ectodomain shedding [PMID:22550340]. Through this TACE-TNF-alpha axis, TIMP3 limits inflammation and downstream MMP2 activation in renal injury, atherosclerosis, autoimmune hepatitis, and diabetic kidney disease, where loss of TIMP3 elevates TACE activity and engages a STAT1-FoxO1 autophagy pathway [PMID:16294222, PMID:19406980, PMID:23401241, PMID:22323541, PMID:24943223]. TIMP3 also broadly restricts metalloproteolysis (MMP2, ADAMs, ADAMTSs) to stabilize the microvasculature and ECM: pericyte-derived, ALK5-induced TIMP3 maintains capillary integrity and prevents fibrosis, microvascular rarefaction, aneurysm, and germinal-matrix hemorrhage [PMID:22383695, PMID:23144462, PMID:29456135]. Beyond protease inhibition, TIMP3 drives caspase-independent endothelial apoptosis requiring VEGFR2 (KDR) by blocking matrix-induced FAK phosphorylation and disrupting focal-adhesion assembly [PMID:25558000]. TIMP3 expression is itself tightly controlled at multiple levels — by the circadian factor CLOCK [PMID:29180440], by chromatin writers/erasers acting at its promoter (KDM1A, HDAC9, MLL1) [PMID:27058897, PMID:30715128, PMID:33653378], and post-transcriptionally by the m6A demethylase ALKBH5 [PMID:31927006]. The Sorsby fundus dystrophy S156C mutation does not impair TIMP3's inhibitory activities but causes pathological ECM accumulation that alters cellular morphology [PMID:12942551, PMID:18295466].","teleology":[{"year":1995,"claim":"Defining the TIMP3 gene architecture and promoter established how its expression is set, including serum-inducible cell-cycle regulation, framing later studies of its transcriptional control.","evidence":"Genomic cloning, chromosomal mapping, and promoter-reporter deletion assays in growth-arrested cells","pmids":["7487894"],"confidence":"High","gaps":["Did not identify the trans-acting factors mediating serum inducibility","No link yet to protein function or substrate spectrum"]},{"year":1997,"claim":"Showing that TIMP3, unlike TIMP-1/-2, is bound exclusively in the ECM and not the medium established its distinctive spatial mode of action as a matrix-tethered inhibitor.","evidence":"ECM-vs-medium fractionation, immunoblot, and IHC in RPE, pericytes, and endothelial cells","pmids":["9068940"],"confidence":"High","gaps":["Molecular basis of ECM retention not defined","Functional consequence of matrix tethering not yet tested"]},{"year":2003,"claim":"Testing the SFD S156C mutation addressed whether disease arises from loss of protease inhibition; it showed the mutant retains MMP-inhibitory activity but abnormally accumulates in ECM and alters cell morphology.","evidence":"MMP activity assays, ECM fractionation, and pulse-chase in S156C knock-in and Timp3-/- fibroblasts","pmids":["12942551"],"confidence":"Medium","gaps":["Mechanism linking ECM accumulation to morphology change unresolved","Single lab; not extended to retinal phenotype in vivo"]},{"year":2005,"claim":"Placing TIMP3 upstream of TACE-mediated TNF-alpha shedding answered how a protease inhibitor governs metabolic inflammation, linking TIMP3 loss to diabetes and vascular inflammation.","evidence":"Insr+/-, Timp3+/-, double-heterozygote mice with TACE activity assays and pharmacological TACE inhibition","pmids":["16294222"],"confidence":"High","gaps":["Did not resolve the structural basis of TIMP3-TACE binding","Tissue-specific contributions not dissected"]},{"year":2007,"claim":"Extending TIMP3 inhibition to ADAM-10/17 in APP processing and to cardiac remodeling broadened its substrate-spectrum and physiological reach to neuronal shedding and post-MI dysfunction.","evidence":"Recombinant TIMP3 with APP fragment/surface-biotinylation analysis (neural cells); Timp3-/- coronary ligation with echocardiography and zymography","pmids":["17913923","17945252"],"confidence":"Medium","gaps":["APP study single-lab, Medium confidence","Direct contribution to human Alzheimer pathology not established"]},{"year":2009,"claim":"Double-knockout epistasis established the TACE-TNF-alpha-MMP2 cascade as the mechanistic chain through which TIMP3 protects the injured kidney.","evidence":"TIMP3-/- and TIMP3-/-/TNFalpha-/- mice, ureteral obstruction, TACE assay, MMP zymography, MMP inhibitor","pmids":["19406980"],"confidence":"High","gaps":["Did not address why MMP2 but not MMP9 is selectively activated","Cell-type source of protective TIMP3 not defined here"]},{"year":2012,"claim":"Dissecting TACE dimerization revealed how TIMP3 inhibition is gated: TIMP3 silences only dimeric TACE, and MAPK-driven monomerization releases the inhibitor to permit shedding.","evidence":"Cell-surface dimerization assays, TIMP3-TACE co-IP, MAPK modulation, TGF-alpha shedding, cytoplasmic-domain mutagenesis","pmids":["22550340"],"confidence":"High","gaps":["Atomic structure of the dimer-TIMP3 complex not resolved","In vivo relevance of dimer state not tested"]},{"year":2012,"claim":"A series of in vivo models established TIMP3 as a tissue-protective regulator across microvascular stability, diabetic kidney injury, aortic aneurysm, and hepatic immune tolerance, often via TACE/MMP2 control.","evidence":"Pericyte 3D tube assays and Timp3-/- kidney injury; Timp3-/-/Akita diabetic mice; Timp3-/-/Mmp2-/- Ang II aneurysm with bone-marrow chimeras; Timp3-/- ConA hepatitis chimeras","pmids":["22383695","22896043","23144462","22323541"],"confidence":"High","gaps":["Organ-selective vulnerability (e.g., kidney vs heart in diabetes) not mechanistically explained","Relative weighting of TACE vs MMP2 contributions varies by tissue"]},{"year":2013,"claim":"Comparative knockouts and a STAT1-FoxO1 rescue defined divergent TIMP roles (TIMP3 protective, TIMP2 injurious) and a transcriptional autophagy arm downstream of TIMP3 in diabetic kidney disease.","evidence":"Timp2-/- vs Timp3-/- ureteral obstruction; diabetic Timp3-/- mice with TIMP3 re-expression, STAT1 knockdown, and human biopsy validation","pmids":["23760282","23401241"],"confidence":"High","gaps":["How extracellular TIMP3 controls intracellular STAT1/FoxO1 not mechanistically connected","TIMP2 opposing mechanism not fully resolved"]},{"year":2014,"claim":"Studies of cardiac fibrosis, atherosclerosis, and hepatocellular carcinoma revealed context-dependent outcomes of TIMP3 loss, including MMP-independent fibrosis, macrophage M1 polarization, and paradoxical tumor protection via senescence.","evidence":"Timp3-/- Ang II hearts with osteopontin/SPARC analysis; ApoE-/-/Timp3-/- atherosclerosis with FACS; Timp3-/- DEN hepatocarcinogenesis with p53/p38/Notch and TNF epistasis","pmids":["24692173","24943223","25347747"],"confidence":"High","gaps":["Mechanism switching TIMP3 between protective and tumor-promoting roles unresolved","MMP-independent fibrotic mechanism only partially defined"]},{"year":2015,"claim":"Establishing a caspase-independent, VEGFR2-dependent FAK-disruption mechanism showed TIMP3 drives endothelial apoptosis separately from its protease-inhibitory function.","evidence":"VEGFR2-expressing vs control cell lines, recombinant TIMP3, FAK phosphorylation, FAK/paxillin co-IP, caspase inhibition, in vivo tumor assay","pmids":["25558000"],"confidence":"High","gaps":["How matrix-bound TIMP3 transduces signal through VEGFR2 to FAK not defined","Direct TIMP3-VEGFR2 binding interface not mapped"]},{"year":2016,"claim":"CADASIL models identified excess TIMP3 as a direct, dose-dependent cause of cerebrovascular dysfunction through ADAM17/HB-EGF inhibition and KV channel upregulation, and a histone demethylase (KDM1A) was shown to silence TIMP3 to enable cancer metastasis.","evidence":"TgNotch3(R169C) and TgBAC-TIMP3 mice with Timp3 haploinsufficiency rescue, patch-clamp, ADAM17/HB-EGF treatment; KDM1A KD/OE with ChIP-qPCR for H3K4me2 and invasion assays","pmids":["27476853","26648042","27058897"],"confidence":"High","gaps":["KDM1A regulation is Medium confidence, single lab","How TIMP3 accumulates in CADASIL not fully explained"]},{"year":2017,"claim":"Hepatocyte-specific TIMP3 gain and ADAM17 loss demonstrated cell-autonomous metabolic protection, placing TIMP3 upstream of hepatocyte ADAM17 in NAFLD, tumorigenesis, and iron handling.","evidence":"AlbT3, hepatocyte and myeloid Adam17 KO mice under HFD, DEN, and iron-overload models with metabolic and ferroportin/MMP readouts","pmids":["28751722","29373036"],"confidence":"High","gaps":["Mechanism by which TIMP3 controls ferroportin not defined","Iron-overload study Medium confidence, single lab"]},{"year":2018,"claim":"Identifying TIMP3 as both an ALK5-induced effector in brain vascular morphogenesis and a CLOCK-dependent circadian gene linked its expression control to developmental signaling and diurnal rhythm.","evidence":"Pericyte-specific Alk5 conditional KO with in vivo TIMP3 rescue; CLOCK and TIMP3 KD/OE in UVB-treated keratinocytes","pmids":["29456135","29180440"],"confidence":"High","gaps":["Circadian regulation Medium confidence, in vitro only","Direct CLOCK occupancy at the TIMP3 locus not shown"]},{"year":2019,"claim":"Biochemical and epigenetic studies refined how TIMP3 activity and expression are tuned: glycosaminoglycans modulate MMP2/TIMP3 complex formation, while HDAC9 represses TIMP3 transcription in trophoblasts.","evidence":"MMP2/TIMP3 complex assays with sulfated hyaluronan/heparin and molecular dynamics; ChIP-qPCR for histone acetylation with HDAC9 knockdown/rescue and invasion assays","pmids":["30894640","30715128"],"confidence":"Medium","gaps":["GAG study lacks mutagenesis validation","HDAC9 axis single lab; preeclampsia causality not established"]},{"year":2020,"claim":"Post-transcriptional and lncRNA-guided chromatin mechanisms (ALKBH5 m6A demethylation and lncRNA ROR-MLL1-H3K4me3) were shown to control TIMP3 levels in cancer, expanding its regulatory layers.","evidence":"RIP-Seq, mRNA stability assays, and xenografts for ALKBH5; RIP, RNA pull-down, ChIP, and xenografts for lncRNA ROR-MLL1","pmids":["31927006","33653378"],"confidence":"Medium","gaps":["Both single-lab studies","Specific m6A sites and their functional weight not mapped"]},{"year":null,"claim":"How matrix-tethered, extracellular TIMP3 transmits signals to intracellular effectors (STAT1/FoxO1, FAK, VEGFR2) and what governs its context-dependent switch between tissue protection and tumor promotion remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of TIMP3 engaging cell-surface receptors","Mechanism integrating its protease-inhibitory and protease-independent functions unclear","Determinants of opposing roles across tissues undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,3,18]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,2,18]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[11]}],"localization":[{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[15,17]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[4,6,9,26]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,3,19,21]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,1,2]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[11,20,22]},{"term_id":"R-HSA-9909396","term_label":"Circadian clock","supporting_discovery_ids":[25]}],"complexes":[],"partners":["ADAM17","ADAM10","MMP2","KDR"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P35625","full_name":"Metalloproteinase inhibitor 3","aliases":["Protein MIG-5","Tissue inhibitor of metalloproteinases 3","TIMP-3"],"length_aa":211,"mass_kda":24.1,"function":"Mediates a variety of processes including matrix regulation and turnover, inflammation, and angiogenesis, through reversible inhibition of zinc protease superfamily enzymes, primarily matrix metalloproteinases (MMPs). Regulates extracellular matrix (ECM) remodeling through inhibition of matrix metalloproteinases (MMP) including MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MMP-14 and MMP-15. Additionally, modulates the processing of amyloid precursor protein (APP) and apolipoprotein E receptor ApoER2 by inhibiting two alpha-secretases ADAM10 and ADAM17 (PubMed:17913923). Functions as a tumor suppressor and a potent inhibitor of angiogenesis. Exerts its anti-angiogenic effect by directly interacting with vascular endothelial growth factor (VEGF) receptor-2/KDR, preventing its binding to the VEGFA ligand (PubMed:12652295). Selectively induces apoptosis in angiogenic endothelial cells through a caspase-independent cell death pathway (PubMed:25558000). Mechanistically, inhibits matrix-induced focal adhesion kinase PTK2 tyrosine phosphorylation and association with paxillin/PXN and disrupts the incorporation of ITGB3, PTK2 and PXN into focal adhesion contacts on the matrix (PubMed:25558000)","subcellular_location":"Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/P35625/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TIMP3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"TMED10","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/TIMP3","total_profiled":1310},"omim":[{"mim_id":"613105","title":"CHOROIDAL DYSTROPHY, CENTRAL AREOLAR 2; CACD2","url":"https://www.omim.org/entry/613105"},{"mim_id":"605670","title":"LATE-ONSET RETINAL DEGENERATION; LORD","url":"https://www.omim.org/entry/605670"},{"mim_id":"605020","title":"VISUAL SYSTEM HOMEOBOX 1; VSX1","url":"https://www.omim.org/entry/605020"},{"mim_id":"601915","title":"TISSUE INHIBITOR OF METALLOPROTEINASE 4; TIMP4","url":"https://www.omim.org/entry/601915"},{"mim_id":"601548","title":"EGF-CONTAINING FIBULIN-LIKE EXTRACELLULAR MATRIX PROTEIN 1; EFEMP1","url":"https://www.omim.org/entry/601548"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Golgi apparatus","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TIMP3"},"hgnc":{"alias_symbol":[],"prev_symbol":["SFD"]},"alphafold":{"accession":"P35625","domains":[{"cath_id":"2.40.50.120","chopping":"26-126","consensus_level":"medium","plddt":96.8866,"start":26,"end":126},{"cath_id":"3.90.370.10","chopping":"128-199","consensus_level":"medium","plddt":90.3857,"start":128,"end":199}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P35625","model_url":"https://alphafold.ebi.ac.uk/files/AF-P35625-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P35625-F1-predicted_aligned_error_v6.png","plddt_mean":87.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TIMP3","jax_strain_url":"https://www.jax.org/strain/search?query=TIMP3"},"sequence":{"accession":"P35625","fasta_url":"https://rest.uniprot.org/uniprotkb/P35625.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P35625/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P35625"}},"corpus_meta":[{"pmid":"22383695","id":"PMC_22383695","title":"Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury.","date":"2012","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/22383695","citation_count":169,"is_preprint":false},{"pmid":"23990326","id":"PMC_23990326","title":"Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion.","date":"2013","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/23990326","citation_count":158,"is_preprint":false},{"pmid":"27756793","id":"PMC_27756793","title":"MicroRNA-181b Controls Atherosclerosis and Aneurysms Through Regulation of TIMP-3 and Elastin.","date":"2016","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/27756793","citation_count":147,"is_preprint":false},{"pmid":"16294222","id":"PMC_16294222","title":"Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16294222","citation_count":143,"is_preprint":false},{"pmid":"22550340","id":"PMC_22550340","title":"TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association.","date":"2012","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/22550340","citation_count":126,"is_preprint":false},{"pmid":"19406980","id":"PMC_19406980","title":"Loss of TIMP3 enhances interstitial nephritis and fibrosis.","date":"2009","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19406980","citation_count":119,"is_preprint":false},{"pmid":"32612540","id":"PMC_32612540","title":"Biology of Tissue Inhibitor of Metalloproteinase 3 (TIMP3), and Its Therapeutic Implications in Cardiovascular Pathology.","date":"2020","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32612540","citation_count":116,"is_preprint":false},{"pmid":"24692173","id":"PMC_24692173","title":"Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction.","date":"2014","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/24692173","citation_count":100,"is_preprint":false},{"pmid":"23401241","id":"PMC_23401241","title":"Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay.","date":"2013","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23401241","citation_count":90,"is_preprint":false},{"pmid":"15599946","id":"PMC_15599946","title":"The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican.","date":"2005","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/15599946","citation_count":87,"is_preprint":false},{"pmid":"32896063","id":"PMC_32896063","title":"CircFNDC3B sequestrates miR-937-5p to derepress TIMP3 and inhibit colorectal cancer progression.","date":"2020","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32896063","citation_count":83,"is_preprint":false},{"pmid":"31927006","id":"PMC_31927006","title":"N6-methyladenosine ALKBH5 promotes non-small cell lung cancer progress by regulating TIMP3 stability.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/31927006","citation_count":79,"is_preprint":false},{"pmid":"26648042","id":"PMC_26648042","title":"Reducing Timp3 or vitronectin ameliorates disease manifestations in CADASIL mice.","date":"2016","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26648042","citation_count":77,"is_preprint":false},{"pmid":"23797704","id":"PMC_23797704","title":"Regulation of TIMP3 in diabetic nephropathy: a role for microRNAs.","date":"2013","source":"Acta diabetologica","url":"https://pubmed.ncbi.nlm.nih.gov/23797704","citation_count":77,"is_preprint":false},{"pmid":"26872030","id":"PMC_26872030","title":"The Angiogenic Effect of microRNA-21 Targeting TIMP3 through the Regulation of MMP2 and MMP9.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26872030","citation_count":77,"is_preprint":false},{"pmid":"11487270","id":"PMC_11487270","title":"Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma.","date":"2001","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11487270","citation_count":77,"is_preprint":false},{"pmid":"14532978","id":"PMC_14532978","title":"Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas.","date":"2003","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/14532978","citation_count":76,"is_preprint":false},{"pmid":"15340428","id":"PMC_15340428","title":"TIMP3 checks inflammation.","date":"2004","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15340428","citation_count":71,"is_preprint":false},{"pmid":"12845640","id":"PMC_12845640","title":"Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development.","date":"2003","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12845640","citation_count":70,"is_preprint":false},{"pmid":"17913923","id":"PMC_17913923","title":"The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis.","date":"2007","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17913923","citation_count":68,"is_preprint":false},{"pmid":"30281655","id":"PMC_30281655","title":"TIMP3 and TIMP1 are risk genes for bicuspid aortic valve and aortopathy in Turner syndrome.","date":"2018","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30281655","citation_count":67,"is_preprint":false},{"pmid":"31624299","id":"PMC_31624299","title":"Loss of TIMP3 by promoter methylation of Sp1 binding site promotes oral cancer metastasis.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31624299","citation_count":67,"is_preprint":false},{"pmid":"25558000","id":"PMC_25558000","title":"Tissue inhibitor of metalloproteinase-3 (TIMP3) promotes endothelial apoptosis via a caspase-independent mechanism.","date":"2015","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/25558000","citation_count":66,"is_preprint":false},{"pmid":"19922547","id":"PMC_19922547","title":"Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas.","date":"2009","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/19922547","citation_count":65,"is_preprint":false},{"pmid":"27476853","id":"PMC_27476853","title":"Mechanistic insights into a TIMP3-sensitive pathway constitutively engaged in the regulation of cerebral hemodynamics.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27476853","citation_count":63,"is_preprint":false},{"pmid":"29796115","id":"PMC_29796115","title":"miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway.","date":"2018","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/29796115","citation_count":62,"is_preprint":false},{"pmid":"31013839","id":"PMC_31013839","title":"Promoter Hypermethylation of Tumor-Suppressor Genes p16INK4a,RASSF1A,TIMP3, and PCQAP/MED15 in Salivary DNA as a Quadruple Biomarker Panel for Early Detection of Oral and Oropharyngeal Cancers.","date":"2019","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/31013839","citation_count":61,"is_preprint":false},{"pmid":"23504349","id":"PMC_23504349","title":"MiR-21 down-regulation suppresses cell growth, invasion and induces cell apoptosis by targeting FASL, TIMP3, and RECK genes in esophageal carcinoma.","date":"2013","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23504349","citation_count":61,"is_preprint":false},{"pmid":"23144462","id":"PMC_23144462","title":"Loss of Timp3 gene leads to abdominal aortic aneurysm formation in response to angiotensin II.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23144462","citation_count":60,"is_preprint":false},{"pmid":"21102583","id":"PMC_21102583","title":"Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression.","date":"2010","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21102583","citation_count":59,"is_preprint":false},{"pmid":"27383203","id":"PMC_27383203","title":"Smad2/3/4 Pathway Contributes to TGF-β-Induced MiRNA-181b Expression to Promote Gastric Cancer Metastasis by Targeting Timp3.","date":"2016","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27383203","citation_count":58,"is_preprint":false},{"pmid":"23760282","id":"PMC_23760282","title":"TIMP2 and TIMP3 have divergent roles in early renal tubulointerstitial injury.","date":"2013","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/23760282","citation_count":56,"is_preprint":false},{"pmid":"25301980","id":"PMC_25301980","title":"Relationship of MMP-14 and TIMP-3 expression with macrophage activation and human atherosclerotic plaque vulnerability.","date":"2014","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/25301980","citation_count":55,"is_preprint":false},{"pmid":"7487894","id":"PMC_7487894","title":"Structure of the human TIMP-3 gene and its cell cycle-regulated promoter.","date":"1995","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/7487894","citation_count":55,"is_preprint":false},{"pmid":"22694820","id":"PMC_22694820","title":"Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer.","date":"2012","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/22694820","citation_count":53,"is_preprint":false},{"pmid":"23819566","id":"PMC_23819566","title":"Promoter methylation and expression of TIMP3 gene in gastric cancer.","date":"2013","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23819566","citation_count":52,"is_preprint":false},{"pmid":"19299578","id":"PMC_19299578","title":"Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia.","date":"2009","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19299578","citation_count":52,"is_preprint":false},{"pmid":"17945252","id":"PMC_17945252","title":"TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction.","date":"2007","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/17945252","citation_count":52,"is_preprint":false},{"pmid":"9068940","id":"PMC_9068940","title":"Discrete expression and distribution pattern of TIMP-3 in the human retina and choroid.","date":"1997","source":"Current eye research","url":"https://pubmed.ncbi.nlm.nih.gov/9068940","citation_count":51,"is_preprint":false},{"pmid":"20194016","id":"PMC_20194016","title":"Loss of expression of TIMP3 in clear cell renal cell carcinoma.","date":"2010","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/20194016","citation_count":49,"is_preprint":false},{"pmid":"29177591","id":"PMC_29177591","title":"MicroRNA-21 promotes proliferation, migration, and invasion of cervical cancer through targeting TIMP3.","date":"2017","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/29177591","citation_count":49,"is_preprint":false},{"pmid":"25065733","id":"PMC_25065733","title":"HPV-positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation.","date":"2014","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25065733","citation_count":49,"is_preprint":false},{"pmid":"29196060","id":"PMC_29196060","title":"miR-365 promotes diabetic retinopathy through inhibiting Timp3 and increasing oxidative stress.","date":"2017","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/29196060","citation_count":47,"is_preprint":false},{"pmid":"24943223","id":"PMC_24943223","title":"Loss of TIMP3 exacerbates atherosclerosis in ApoE null mice.","date":"2014","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/24943223","citation_count":44,"is_preprint":false},{"pmid":"22896043","id":"PMC_22896043","title":"Loss of TIMP3 selectively exacerbates diabetic nephropathy.","date":"2012","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22896043","citation_count":42,"is_preprint":false},{"pmid":"27058897","id":"PMC_27058897","title":"KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27058897","citation_count":40,"is_preprint":false},{"pmid":"32724322","id":"PMC_32724322","title":"Curcumin Inhibits Hepatocellular Carcinoma via Regulating miR-21/TIMP3 Axis.","date":"2020","source":"Evidence-based complementary and alternative medicine : eCAM","url":"https://pubmed.ncbi.nlm.nih.gov/32724322","citation_count":40,"is_preprint":false},{"pmid":"32271187","id":"PMC_32271187","title":"Pregnancy-associated Inflammatory Myofibroblastic Tumors of the Uterus Are Clinically Distinct and Highly Enriched for TIMP3-ALK and THBS1-ALK Fusions.","date":"2020","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32271187","citation_count":40,"is_preprint":false},{"pmid":"16507410","id":"PMC_16507410","title":"DNA hypermethylation of TIMP3 gene in invasive breast ductal carcinoma.","date":"2005","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/16507410","citation_count":39,"is_preprint":false},{"pmid":"29456135","id":"PMC_29456135","title":"Pericyte ALK5/TIMP3 Axis Contributes to Endothelial Morphogenesis in the Developing Brain.","date":"2018","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/29456135","citation_count":39,"is_preprint":false},{"pmid":"28404876","id":"PMC_28404876","title":"Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28404876","citation_count":39,"is_preprint":false},{"pmid":"24221409","id":"PMC_24221409","title":"Differential TIMP3 expression affects tumor progression and angiogenesis in melanomas through regulation of directionally persistent endothelial cell migration.","date":"2013","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24221409","citation_count":38,"is_preprint":false},{"pmid":"36164322","id":"PMC_36164322","title":"Exosomal miR-452-5p Induce M2 Macrophage Polarization to Accelerate Hepatocellular Carcinoma Progression by Targeting TIMP3.","date":"2022","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/36164322","citation_count":38,"is_preprint":false},{"pmid":"25171061","id":"PMC_25171061","title":"TIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCC.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25171061","citation_count":38,"is_preprint":false},{"pmid":"28236165","id":"PMC_28236165","title":"Mechanosensitive microRNA-181b Regulates Aortic Valve Endothelial Matrix Degradation by Targeting TIMP3.","date":"2017","source":"Cardiovascular engineering and technology","url":"https://pubmed.ncbi.nlm.nih.gov/28236165","citation_count":37,"is_preprint":false},{"pmid":"24359512","id":"PMC_24359512","title":"TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased incidence of second primary tumors.","date":"2013","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24359512","citation_count":36,"is_preprint":false},{"pmid":"11879143","id":"PMC_11879143","title":"Novel mutation in the TIMP3 gene causes Sorsby fundus dystrophy.","date":"2002","source":"Archives of ophthalmology (Chicago, Ill. : 1960)","url":"https://pubmed.ncbi.nlm.nih.gov/11879143","citation_count":35,"is_preprint":false},{"pmid":"31877820","id":"PMC_31877820","title":"The Diverse Roles of TIMP-3: Insights into Degenerative Diseases of the Senescent Retina and Brain.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31877820","citation_count":35,"is_preprint":false},{"pmid":"7925969","id":"PMC_7925969","title":"Expression of TIMP3 mRNA is elevated in retinas affected by simplex retinitis pigmentosa.","date":"1994","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/7925969","citation_count":35,"is_preprint":false},{"pmid":"25819812","id":"PMC_25819812","title":"MiR-191 modulates malignant transformation of endometriosis through regulating TIMP3.","date":"2015","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/25819812","citation_count":34,"is_preprint":false},{"pmid":"32309847","id":"PMC_32309847","title":"MiR-770-5p facilitates podocyte apoptosis and inflammation in diabetic nephropathy by targeting TIMP3.","date":"2020","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/32309847","citation_count":34,"is_preprint":false},{"pmid":"30715128","id":"PMC_30715128","title":"Dysregulation of HDAC9 Represses Trophoblast Cell Migration and Invasion Through TIMP3 Activation in Preeclampsia.","date":"2019","source":"American journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/30715128","citation_count":32,"is_preprint":false},{"pmid":"28539838","id":"PMC_28539838","title":"Andrographolide Inhibits Angiogenesis by Inhibiting the Mir-21-5p/TIMP3 Signaling Pathway.","date":"2017","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28539838","citation_count":32,"is_preprint":false},{"pmid":"33960555","id":"PMC_33960555","title":"CircSLC7A2 protects against osteoarthritis through inhibition of the miR-4498/TIMP3 axis.","date":"2021","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/33960555","citation_count":31,"is_preprint":false},{"pmid":"26686417","id":"PMC_26686417","title":"The imbalance between TIMP3 and matrix-degrading enzymes plays an important role in intervertebral disc degeneration.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26686417","citation_count":31,"is_preprint":false},{"pmid":"31933879","id":"PMC_31933879","title":"LncRNA TUG1 ameliorates diabetic nephropathy by inhibiting miR-21 to promote TIMP3-expression.","date":"2019","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31933879","citation_count":31,"is_preprint":false},{"pmid":"26749283","id":"PMC_26749283","title":"TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26749283","citation_count":30,"is_preprint":false},{"pmid":"32631441","id":"PMC_32631441","title":"Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage.","date":"2020","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/32631441","citation_count":30,"is_preprint":false},{"pmid":"27073718","id":"PMC_27073718","title":"MicroRNA-373 promotes migration and invasion in human esophageal squamous cell carcinoma by inhibiting TIMP3 expression.","date":"2015","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27073718","citation_count":30,"is_preprint":false},{"pmid":"16989765","id":"PMC_16989765","title":"A novel His158Arg mutation in TIMP3 causes a late-onset form of Sorsby fundus dystrophy.","date":"2006","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/16989765","citation_count":30,"is_preprint":false},{"pmid":"22323541","id":"PMC_22323541","title":"Stromal TIMP3 regulates liver lymphocyte populations and provides protection against Th1 T cell-driven autoimmune hepatitis.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22323541","citation_count":29,"is_preprint":false},{"pmid":"33653378","id":"PMC_33653378","title":"Long non-coding RNA ROR recruits histone transmethylase MLL1 to up-regulate TIMP3 expression and promote breast cancer progression.","date":"2021","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33653378","citation_count":29,"is_preprint":false},{"pmid":"12942551","id":"PMC_12942551","title":"Sorsby fundus dystrophy mutation Timp3(S156C) affects the morphological and biochemical phenotype but not metalloproteinase homeostasis.","date":"2003","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12942551","citation_count":28,"is_preprint":false},{"pmid":"16900752","id":"PMC_16900752","title":"Expression of ADAMTS-1, -4, -5 and TIMP-3 in normal and multiple sclerosis CNS white matter.","date":"2006","source":"Multiple sclerosis (Houndmills, Basingstoke, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16900752","citation_count":28,"is_preprint":false},{"pmid":"23172037","id":"PMC_23172037","title":"Promoter hypomethylation of TIMP3 is associated with pre-eclampsia in a Chinese population.","date":"2012","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/23172037","citation_count":28,"is_preprint":false},{"pmid":"19835597","id":"PMC_19835597","title":"Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.","date":"2009","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19835597","citation_count":27,"is_preprint":false},{"pmid":"34390329","id":"PMC_34390329","title":"A circular RNA, circSMARCA5, inhibits prostate cancer proliferative, migrative, and invasive capabilities via the miR-181b-5p/miR-17-3p-TIMP3 axis.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/34390329","citation_count":27,"is_preprint":false},{"pmid":"27522248","id":"PMC_27522248","title":"Tissue inhibitor of metalloproteinase-3 (TIMP3) expression decreases during melanoma progression and inhibits melanoma cell migration.","date":"2016","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/27522248","citation_count":27,"is_preprint":false},{"pmid":"30415251","id":"PMC_30415251","title":"MicroRNA-323a-3p Promotes Pressure Overload-Induced Cardiac Fibrosis by Targeting TIMP3.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30415251","citation_count":27,"is_preprint":false},{"pmid":"28751722","id":"PMC_28751722","title":"Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28751722","citation_count":26,"is_preprint":false},{"pmid":"16259644","id":"PMC_16259644","title":"TIMP3 mutation in Sorsby's fundus dystrophy: molecular insights.","date":"2005","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16259644","citation_count":26,"is_preprint":false},{"pmid":"30584323","id":"PMC_30584323","title":"miR-222-3p promotes osteosarcoma cell migration and invasion through targeting TIMP3.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30584323","citation_count":26,"is_preprint":false},{"pmid":"29180440","id":"PMC_29180440","title":"TIMP3 is a CLOCK-dependent diurnal gene that inhibits the expression of UVB-induced inflammatory cytokines in human keratinocytes.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29180440","citation_count":26,"is_preprint":false},{"pmid":"21984580","id":"PMC_21984580","title":"Decreased IRS2 and TIMP3 expression in monocytes from offspring of type 2 diabetic patients is correlated with insulin resistance and increased intima-media thickness.","date":"2011","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/21984580","citation_count":26,"is_preprint":false},{"pmid":"15714128","id":"PMC_15714128","title":"Alterations of the tissue inhibitor of metalloproteinase-3 (TIMP3) gene in pancreatic adenocarcinomas.","date":"2005","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/15714128","citation_count":26,"is_preprint":false},{"pmid":"25347747","id":"PMC_25347747","title":"TIMP3 controls cell fate to confer hepatocellular carcinoma resistance.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25347747","citation_count":25,"is_preprint":false},{"pmid":"25807548","id":"PMC_25807548","title":"Timp3 deficient mice show resistance to developing breast cancer.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25807548","citation_count":24,"is_preprint":false},{"pmid":"37783408","id":"PMC_37783408","title":"Asiaticoside-nitric oxide promoting diabetic wound healing through the miRNA-21-5p/TGF-β1/SMAD7/TIMP3 signaling pathway.","date":"2023","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37783408","citation_count":24,"is_preprint":false},{"pmid":"27077469","id":"PMC_27077469","title":"MiR-221 Exacerbate Cell Proliferation and Invasion by Targeting TIMP3 in Papillary Thyroid Carcinoma.","date":"2017","source":"American journal of therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/27077469","citation_count":24,"is_preprint":false},{"pmid":"23598435","id":"PMC_23598435","title":"Ultrasound-targeted HSVtk and Timp3 gene delivery for synergistically enhanced antitumor effects in hepatoma.","date":"2013","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23598435","citation_count":24,"is_preprint":false},{"pmid":"30894640","id":"PMC_30894640","title":"Glycosaminoglycans influence enzyme activity of MMP2 and MMP2/TIMP3 complex formation - Insights at cellular and molecular level.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30894640","citation_count":24,"is_preprint":false},{"pmid":"31921636","id":"PMC_31921636","title":"A Strong Decrease in TIMP3 Expression Mediated by the Presence of miR-17 and 20a Enables Extracellular Matrix Remodeling in the NSCLC Lesion Surroundings.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31921636","citation_count":24,"is_preprint":false},{"pmid":"29373036","id":"PMC_29373036","title":"TIMP3 deficiency exacerbates iron overload-mediated cardiomyopathy and liver disease.","date":"2018","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29373036","citation_count":23,"is_preprint":false},{"pmid":"22848309","id":"PMC_22848309","title":"Expression of MMP-3 and TIMP-3 in gastric cancer tissue and its clinical significance.","date":"2011","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/22848309","citation_count":23,"is_preprint":false},{"pmid":"27222429","id":"PMC_27222429","title":"Expression and inhibitory role of TIMP-3 in hepatocellular carcinoma.","date":"2016","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/27222429","citation_count":22,"is_preprint":false},{"pmid":"18295466","id":"PMC_18295466","title":"Molecular dissection of TIMP3 mutation S156C associated with Sorsby fundus dystrophy.","date":"2008","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/18295466","citation_count":22,"is_preprint":false},{"pmid":"22053204","id":"PMC_22053204","title":"TIMP3 regulates mammary epithelial apoptosis with immune cell recruitment through differential TNF dependence.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22053204","citation_count":22,"is_preprint":false},{"pmid":"33560588","id":"PMC_33560588","title":"CircCSNK1G3 up-regulates miR-181b to promote growth and metastasis via TIMP3-mediated epithelial to mesenchymal transitions in renal cell carcinoma.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33560588","citation_count":21,"is_preprint":false},{"pmid":"29775626","id":"PMC_29775626","title":"MicroRNA-21 up-regulates metalloprotease by down-regulating TIMP3 during cumulus cell-oocyte complex in vitro maturation.","date":"2018","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29775626","citation_count":21,"is_preprint":false},{"pmid":"22735305","id":"PMC_22735305","title":"Expression of ADAMTS-1, ADAMTS-4, ADAMTS-5 and TIMP3 by hepatocellular carcinoma cell lines.","date":"2012","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22735305","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53858,"output_tokens":9136,"usd":0.149307,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19365,"output_tokens":5738,"usd":0.120137,"stage2_stop_reason":"end_turn"},"total_usd":0.269444,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"TIMP3 directly inhibits TACE (ADAM17), the TNF-alpha-converting enzyme. In insulin receptor heterozygous (Insr+/-) mice, TIMP3 deficiency led to unchecked TACE activity, increased soluble TNF-alpha, and subsequent diabetes and vascular inflammation. Pharmacological TACE inhibition reduced hyperglycemia, and Tace+/- mice showed increased insulin sensitivity, placing TIMP3 upstream of TACE-mediated TNF-alpha shedding in a metabolic/inflammatory pathway.\",\n      \"method\": \"Genetic mouse models (Insr+/-, Timp3+/-, double heterozygotes), TACE activity assays, TNF-alpha measurement, pharmacological TACE inhibition\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models, pharmacological rescue, and epistasis in vivo; replicated across multiple experimental conditions in one rigorous study\",\n      \"pmids\": [\"16294222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TACE (ADAM17) exists predominantly as dimers at the cell surface under basal conditions; dimerization requires its cytoplasmic domain and enables efficient association with TIMP3, which silences TACE activity. Upon ERK or p38 MAPK activation, the dimer-to-monomer shift decreases TIMP3 association and increases TACE-mediated ectodomain shedding of TGF-alpha, establishing TIMP3 as a dimer-dependent inhibitor of TACE.\",\n      \"method\": \"Cell-surface TACE dimerization assays, co-immunoprecipitation of TIMP3 with TACE, MAPK pathway activation/inhibition, TGF-alpha shedding assays, cytoplasmic domain mutagenesis\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mechanistic dissection using mutagenesis, co-IP, and functional shedding assays in one rigorous study\",\n      \"pmids\": [\"22550340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TIMP3 inhibits alpha-secretase cleavage of amyloid precursor protein (APP) and ApoER2 by blocking ADAM-10 and ADAM-17. TIMP3 decreased surface levels of ADAM-10, APP, and ApoER2, increased APP beta-CTF and Abeta production, and directed APP toward endocytosis and beta-secretase cleavage rather than alpha-secretase cleavage.\",\n      \"method\": \"Recombinant TIMP3 treatment, ADAM-10/17 activity assays, Western blot for APP processing fragments, surface biotinylation, cell transfection in neuroblastoma/glia/COS7 cells\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (surface labeling, fragment analysis, activity assay) in single lab\",\n      \"pmids\": [\"17913923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TIMP3 deficiency in mice leads to accelerated TACE activity and elevated soluble TNF-alpha after ureteral obstruction, followed by enhanced MMP2 (but not MMP9) activation, increased fibrosis, and apoptosis. Additional deletion of TNF-alpha in TIMP3-/- mice markedly reduced inflammation and MMP induction, placing TIMP3 upstream of TACE-TNF-alpha-MMP signaling in renal injury.\",\n      \"method\": \"Genetic knockout mice (TIMP3-/-, TIMP3-/-/TNFalpha-/-), unilateral ureteral obstruction model, TACE activity assay, MMP zymography, histopathology, MMP inhibitor treatment\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — double-knockout epistasis, pharmacological inhibition, and multiple orthogonal biochemical readouts\",\n      \"pmids\": [\"19406980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TIMP3 stabilizes capillary tube networks and inhibits metalloproteolytic activity and angiogenic signaling in endothelial cells; this function is lost when pericytes transition to myofibroblasts. Pericyte-derived TIMP3 (in contrast to ADAMTS1) maintains microvascular stability, and Timp3-/- mice have spontaneous microvascular rarefaction and exaggerated fibrotic response to injury.\",\n      \"method\": \"3D capillary tube assays, Timp3-/- mice, in vivo kidney injury models, pericyte-myofibroblast differentiation assays, metalloproteolytic activity assays\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro 3D assay, genetic knockout, and in vivo injury model with mechanistic readouts\",\n      \"pmids\": [\"22383695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Loss of TIMP3 in the Akita diabetic mouse background selectively exacerbates diabetic renal injury (albuminuria, mesangial expansion, kidney hypertrophy) with elevated TACE activity, increased reactive oxygen species, NADPH oxidase activity, and PKCbeta1 elevation; cardiac function was unaffected, demonstrating a kidney-selective protective role of TIMP3 in diabetes.\",\n      \"method\": \"Double-mutant mice (TIMP3-/-/Akita), albuminuria measurement, TACE activity assay, ROS/NADPH oxidase assays, Western blot for PKC isoforms and signaling molecules\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — organ-specific genetic epistasis with multiple mechanistic pathway analyses\",\n      \"pmids\": [\"22896043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Timp3 deficiency in Ang II-infused mice causes abdominal aortic aneurysm (AAA) with reduced collagen and elastin proteins (not mRNA), elevated MMP2 and broad proteolytic activities. Additional deletion of Mmp2 exacerbated AAA and rupture; bone marrow reconstitution with WT cells in Timp3-/-/Mmp2-/- mice reduced inflammation and prevented AAA, identifying an MMP-dependent and bone marrow inflammatory component downstream of TIMP3.\",\n      \"method\": \"Timp3-/- mice, Ang II infusion, Mmp2-/- double knockout, bone marrow transplantation, MMP inhibitor (PD166793) treatment, zymography, protein/mRNA analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models, pharmacological inhibition, and bone marrow chimera rescue in one comprehensive study\",\n      \"pmids\": [\"23144462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TIMP3 deficiency in diabetic mice leads to reduced FoxO1 expression and its autophagy-related targets, with increased STAT1. Re-expression of TIMP3 in Timp3-/- mesangial cells rescued FoxO1 and its targets and decreased STAT1, establishing a TIMP3 → STAT1 → FoxO1 pathway in diabetic kidney disease.\",\n      \"method\": \"Diabetic Timp3-/- mice, microarray profiling, TIMP3 re-expression in mesangial cells, qPCR/Western blot for FoxO1, STAT1 knockdown rescue experiments, human kidney biopsy validation\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model, in vitro rescue, STAT1 knockdown epistasis, and human tissue validation\",\n      \"pmids\": [\"23401241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In renal injury after ureteral obstruction, TIMP3 deficiency (but not TIMP2 deficiency) increases MMP2 activation, TACE activity, caspase-3 activity, and fibrosis through collagen I/III, CTGF, TGF-beta/Smad2/3 pathway activation. TIMP2 deficiency blocks MMP2 activation and reduces fibrosis, demonstrating divergent and opposing roles: TIMP3 protects from damage while TIMP2 promotes injury through MMP2 activation.\",\n      \"method\": \"Timp2-/- and Timp3-/- mice, unilateral ureteral obstruction, gene microarray, zymography for MMP2 activation, TACE activity assay, caspase assay, histopathology\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — comparative genetic knockouts with multiple orthogonal mechanistic readouts\",\n      \"pmids\": [\"23760282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In Ang II-infused mice, TIMP3 deficiency produces excess fibrosis (without hypertrophy) involving post-translational stabilization and deposition of collagen by matricellular proteins osteopontin and SPARC, increased inflammation, and elevated TACE activity; this is distinct from TIMP2 deficiency effects and appears independent of canonical MMP-inhibitory function.\",\n      \"method\": \"TIMP2-/- and TIMP3-/- mice, Ang II infusion, adult cardiomyocyte/fibroblast co-culture, cyclic stretch assays, Western blot for osteopontin and SPARC, collagen quantification, TACE activity assay\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — comparative genetic models, in vitro co-culture mechanistic follow-up, multiple orthogonal biochemical assays\",\n      \"pmids\": [\"24692173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TIMP3 deficiency accelerates maladaptive cardiac remodeling after myocardial infarction, with greater left ventricular dilation, increased gelatinase MMP activity, elevated TNF-alpha levels, increased blood vessel density, cell proliferation, apoptosis in infarct area, and reduced collagen in remote myocardium, resulting in accelerated systolic dysfunction and higher mortality.\",\n      \"method\": \"Timp3-/- mice, coronary artery ligation, echocardiography, pressure-volume measurements, MMP zymography, histopathology, ELISA for TNF-alpha\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO model, multiple functional and biochemical readouts with temporal resolution\",\n      \"pmids\": [\"17945252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TIMP3 promotes apoptosis in endothelial cells via a caspase-independent mechanism. The apoptotic activity is independent of MMP inhibitory activity and requires KDR (VEGFR2) expression. TIMP3 inhibits matrix-induced focal adhesion kinase (FAK) tyrosine phosphorylation, disrupts FAK association with paxillin, and prevents incorporation of beta3 integrin, FAK, and paxillin into focal adhesion contacts, an effect not reversed by caspase inhibitors.\",\n      \"method\": \"PAE/KDR vs PAE/beta-R cell lines, recombinant TIMP3 treatment, caspase inhibitor treatment, FAK phosphorylation assay, co-immunoprecipitation of FAK/paxillin, immunofluorescence of focal adhesions, in vivo tumor assay with TIMP3-overexpressing breast carcinoma cells\",\n      \"journal\": \"Apoptosis : an international journal on programmed cell death\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (co-IP, phosphorylation assay, pharmacological inhibition, receptor-specific cell lines) with mechanistic pathway dissection\",\n      \"pmids\": [\"25558000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TIMP3 accumulation in CADASIL acts through inhibition of ADAM17 and HB-EGF to regulate cerebral arterial tone and blood flow responses. In CADASIL mice, exogenous ADAM17 or HB-EGF restored cerebrovascular responses. Upregulated voltage-dependent potassium channel (KV) number in cerebral arterial myocytes was identified as a downstream effector of TIMP3-induced cerebrovascular deficits.\",\n      \"method\": \"TgNotch3(R169C) CADASIL mouse model, TgBAC-TIMP3 overexpressing mice, Timp3 haploinsufficiency rescue, cerebral blood flow measurements, ex vivo arterial tone assays, patch-clamp for KV channels, ADAM17/HB-EGF exogenous treatment\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models, pharmacological rescue, electrophysiological measurements, and mechanistic pathway tracing in one study\",\n      \"pmids\": [\"27476853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In CADASIL mice, elevated TIMP3 (but not Notch3 ECD deposition) impairs cerebral blood flow autoregulation and functional hyperemia. Haploinsufficiency of Timp3 rescues cerebrovascular reactivity deficits. A separate TgBAC-TIMP3 overexpressing mouse also displays attenuated myogenic responses of brain arteries, confirming TIMP3 level as a direct determinant of cerebrovascular function.\",\n      \"method\": \"TgNotch3(R169C) mice with Timp3 haploinsufficiency, TgBAC-TIMP3 transgenic mice, cerebral blood flow measurements (laser Doppler), ex vivo pressurized artery myogenic response assays\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent transgenic/knockout models with direct functional vascular measurements\",\n      \"pmids\": [\"26648042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Pericyte ALK5 (TGF-beta receptor) signaling upregulates TIMP3 expression; pericyte-specific ALK5 knockout in embryonic mice downregulates TIMP3, leading to germinal matrix hemorrhage with abnormal microvessel dilation, reduced pericyte coverage, EC hyperproliferation, and enhanced perivascular MMP activity. Exogenous TIMP3 administration to ALK5-mutant embryos improved endothelial morphogenesis and attenuated hemorrhage, placing TIMP3 downstream of pericyte ALK5 in brain vascular morphogenesis.\",\n      \"method\": \"Pericyte-specific Alk5 conditional knockout mice, TIMP3 protein administration in vivo, histopathology, MMP activity assays, quantification of vascular phenotypes\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional genetic KO, in vivo protein rescue, and multiple vascular readouts\",\n      \"pmids\": [\"29456135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TIMP3 is expressed and secreted by retinal pigment epithelium (RPE), choroidal microcapillary endothelium, and pericytes. Unlike TIMP-1 and -2 (which are secreted into culture medium), TIMP3 localizes exclusively to the extracellular matrix and is not found in conditioned medium. In vivo, TIMP3 immunostaining is pronounced in Bruch's membrane, particularly near RPE and endothelial basement membranes.\",\n      \"method\": \"RT-PCR, Northern analysis, Western immunoblot of conditioned medium vs ECM fractions, immunohistochemistry of retina/choroid sections, cultured RPE/pericyte/endothelial cells\",\n      \"journal\": \"Current eye research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct fractionation experiments (ECM vs. medium) with multiple cell types and in vivo IHC validation\",\n      \"pmids\": [\"9068940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The human TIMP3 gene is TATA-less, initiates transcription at one major site, consists of five exons and four introns spanning ~30 kb, maps to chromosome 22q13.1, and gives rise to three distinct mRNAs via alternative polyadenylation. The first 112 bases of the promoter (containing multiple Sp1 sites) confer high basal expression; the region from -463 to -112 is a major determinant of serum inducibility, conferring cell cycle regulation.\",\n      \"method\": \"Genomic cloning and sequencing, somatic cell hybrid mapping, promoter-reporter deletion assays, serum stimulation of growth-arrested cells\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct promoter mapping with deletion reporter assays and chromosomal mapping\",\n      \"pmids\": [\"7487894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The SFD-associated S156C mutation in TIMP3 does not affect MMP inhibitory activity or metalloproteinase homeostasis in fibroblasts derived from mutant mice. Instead, mutant TIMP3(S156C) accumulates in the ECM (not due to altered turnover rate) and this accumulation alters cellular morphology. Loss of TIMP3 function in determining cellular morphology (not protease inhibition) is proposed as the pathogenic mechanism.\",\n      \"method\": \"Immortalized fibroblasts from Timp3-/- and Timp3(S156C/S156C) mice, MMP activity assays, ECM fractionation, pulse-chase for turnover rates, phenotypic analysis\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct enzyme activity assays and ECM fractionation in defined genetic cell lines; single lab\",\n      \"pmids\": [\"12942551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The S156C SFD mutation does not impair TIMP3's inhibitory activities toward TACE, ADAMTS4/5, aggrecan-cleaving MMPs, or its anti-angiogenic properties in fibrin bead assays. TIMP3 S156C blocks VEGF binding to VEGFR2 to the same extent as wild-type TIMP3. In contrast, Timp3-/- tissue shows significantly enhanced TACE activity (but not ADAMTS4/5 or MMP activity), suggesting compensatory inhibitors for the latter enzymes.\",\n      \"method\": \"Timp3 S156C knock-in and Timp3-/- mice, TACE/ADAMTS4/5/MMP activity assays from tissue extracts, fibrin bead angiogenesis assay, VEGF-VEGFR2 binding assay with recombinant proteins, rescue with recombinant TIMP3\",\n      \"journal\": \"Matrix biology : journal of the International Society for Matrix Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with recombinant proteins, multiple enzyme activity assays, genetic models, functional angiogenesis assay in one study\",\n      \"pmids\": [\"18295466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TIMP3 deficiency leads to spontaneous accumulation and activation of hepatic CD4+, CD8+, and NKT cells. In Con A-induced autoimmune hepatitis, Timp3-/- mice have a greatly enhanced Th1 cytokine response and acute liver failure that mechanistically depends on TNF signaling. Bone marrow chimera experiments established that hepatic stromal (not hematopoietic) TIMP3 provides protection, with hepatocytes identified as the major source of Timp3 in resting liver.\",\n      \"method\": \"Timp3-/- mice, Con A model, bone marrow chimeras, flow cytometry of liver lymphocyte populations, Tnf genetic crosses, in situ hybridization/immunostaining for cell-type-specific Timp3 expression\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — bone marrow chimera epistasis, TNF genetic interaction, multiple cell-type characterization\",\n      \"pmids\": [\"22323541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TIMP3 deficiency leads to TNF dysregulation, earlier caspase activation, accelerated mitochondrial apoptosis, faster loss of STAT3 and TGFbeta3, E-cadherin fragmentation, accelerated adipogenesis, and greater macrophage/T-cell infiltration during mammary gland involution. Crossing in Tnf deficiency abrogated caspase-3 activation but paradoxically heightened macrophage/T-cell influx, showing that TIMP3 differentially controls apoptosis (TNF-dependent) and inflammatory cell infiltration (TNF-independent) during involution.\",\n      \"method\": \"Timp3-/- and Timp3-/-/Tnf-/- mice, mammary gland involution model, caspase activity assays, Western blot for signaling molecules, flow cytometry/histopathology for immune cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — double-knockout epistasis dissecting TNF-dependent vs. independent pathways with multiple orthogonal readouts\",\n      \"pmids\": [\"22053204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TIMP3 loss in ApoE-/- mice increases atherosclerosis with greater macrophage plaque infiltration, elevated serum MCP-1, and expansion of inflammatory (M1) Gr1+ macrophages in circulation and aortic tissue, establishing TIMP3 as a regulator of macrophage inflammatory polarization in atherosclerosis.\",\n      \"method\": \"ApoE-/-/Timp3-/- double-knockout mice, en face aorta analysis, aortic root histology, FACS for macrophage subsets, serum MCP-1 ELISA, metabolomics\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model with multiple vascular and immunological readouts\",\n      \"pmids\": [\"24943223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Genetic loss of Timp3 protects mice from carcinogen-induced hepatocellular carcinoma (HCC): all WT mice developed HCC by 12 months, while only 33% of Timp3-/- mice did. Protection occurs through precocious activation of p53, p38, and Notch pathways, leading to hepatocyte senescence rather than apoptosis; TNF signaling was dispensable for this protection.\",\n      \"method\": \"Timp3-/- mice, diethylnitrosamine carcinogen model, immunohistochemistry and Western blot for p53/p38/Notch, senescence assays (SA-beta-Gal), apoptosis assays, Timp3-/-/Tnf-/- epistasis, Timp3-/- mouse embryo fibroblasts\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic KO with pathway analysis, TNF epistasis, and in vitro corroboration\",\n      \"pmids\": [\"25347747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In MMTV-PyMT and MMTV-Neu breast cancer models, Timp3 loss delays tumor onset and some mice remain tumor-free. The tumor-suppression in Timp3-null mice requires TNFR1 signaling. Transplantation experiments showed that Timp3 deficiency in the host stroma (not tumor cells) is sufficient to delay early but not advanced tumor growth.\",\n      \"method\": \"MMTV-PyMT/Timp3-/- and MMTV-Neu/Timp3-/- mice, Tnfr1 genetic crosses (epistasis), tumor cell transplantation into Timp3-/- hosts, tumor onset/incidence measurement\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic crosses, epistasis with TNFR1, and transplantation experiment identifying spatial requirement\",\n      \"pmids\": [\"25807548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hepatocyte-specific TIMP3 overexpression (AlbT3 mice) improved glucose metabolism, hepatic fatty acid oxidation, and cholesterol homeostasis during high-fat diet. This was linked to regulation of ADAM17: hepatocyte-specific Adam17 knockout (A17LKO, but not myeloid Adam17 KO) similarly improved liver steatosis, placing TIMP3 upstream of hepatocyte ADAM17 in NAFLD protection. Both AlbT3 and A17LKO mice showed reduced hepatic tumorigenesis.\",\n      \"method\": \"Hepatocyte-specific TIMP3 transgenic (AlbT3), hepatocyte-specific Adam17 KO (A17LKO), myeloid-specific Adam17 KO (A17MKO) mice, HFD model, diethylnitrosamine tumor model, metabolic phenotyping, gene expression analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific transgenic and KO models with genetic epistasis between TIMP3 and ADAM17\",\n      \"pmids\": [\"28751722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TIMP3 is a CLOCK-dependent diurnal gene in human keratinocytes: CLOCK knockdown reduces TIMP3 expression rhythmically, and TIMP3 inversely regulates MMP-1 and inflammatory cytokines (TNF-alpha, CXCL1, IL-8). UVB exposure downregulates both CLOCK and TIMP3, increasing TNF-alpha secretion and CXCL1/IL-8 transcription via C/EBP-alpha. TIMP3 overexpression decreases, and knockdown increases, UVB-induced TNF-alpha secretion.\",\n      \"method\": \"CLOCK knockdown in keratinocytes, TIMP3 KD/OE, UVB irradiation, MMP-1 activity assay, ELISA for TNF-alpha, qPCR/Western blot for cytokines, circadian rhythm monitoring\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple KD/OE experiments with functional cytokine readouts; single lab, in vitro\",\n      \"pmids\": [\"29180440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Glycosaminoglycans (specifically sulfated hyaluronan and heparin) influence MMP2/TIMP3 complex formation and MMP2 inhibition. Sulfated hyaluronan supports fibrillar co-alignment of MMP2 and TIMP3, stabilizing interactions between MMP2 hemopexin domain and TIMP3 C-terminal tail. Molecular modeling indicates that GAG can either support or preclude TIMP3-mediated MMP2 inhibition depending on the sequential order of complex formation.\",\n      \"method\": \"In vitro MMP2 activity assays with bone marrow stromal cells, MMP2/TIMP3 complex formation assays, in silico docking and molecular dynamics simulations, immunofluorescence imaging of fibrillar structures\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro biochemical assay with structural modeling; single lab, no mutagenesis validation\",\n      \"pmids\": [\"30894640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"KDM1A (histone demethylase) promotes lung cancer metastasis by silencing TIMP3 through H3K4me2 demethylation at the TIMP3 promoter. KDM1A knockdown increases TIMP3, which in turn inhibits MMP2 expression and JNK phosphorylation. Restoring TIMP3 expression in KDM1A-deficient cells inhibits invasion/migration, and TIMP3 knockdown in KDM1A-deficient cells rescues metastatic capability.\",\n      \"method\": \"KDM1A KD/OE in NSCLC cells, ChIP-qPCR for H3K4me2 at TIMP3 promoter, TIMP3 KD rescue experiment, MMP2 activity assay, JNK phosphorylation assay, Transwell invasion assay, pharmacological inhibition\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for histone mark, epistasis rescue experiment, functional invasion assay; single lab\",\n      \"pmids\": [\"27058897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hepatocyte-specific TIMP3 overexpression or Adam17 deletion protected against iron overload-mediated cardiac dysfunction and liver injury. In Timp3-/- mice with iron overload, constituently lower ferroportin levels led to twofold higher hepatic iron accumulation, increased MMP-2 activation, and greater hepatic inflammatory cytokine and MMP-12/13 expression.\",\n      \"method\": \"Timp3-/- mice, chronic iron overload model, echocardiography, hepatic iron quantification, ferroportin Western blot, MMP zymography, gelatinase activity assay, histopathology\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model with multiple mechanistic readouts; single lab\",\n      \"pmids\": [\"29373036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HDAC9 promotes trophoblast cell migration and invasion by repressing TIMP3 transcription through promoter histone hypoacetylation. In preeclampsia, HDAC9 is downregulated in syncytiotrophoblasts; HDAC9 knockdown increases histone acetylation at the TIMP3 promoter (confirmed by ChIP-qPCR), elevates TIMP3 expression, and inhibits cell migration and invasion in HTR-8/SVneo cells.\",\n      \"method\": \"ChIP-qPCR for histone acetylation at TIMP3 promoter, HDAC9 siRNA knockdown and rescue, Transwell migration/invasion assays, RT-qPCR and Western blot, immunohistochemistry in human placentas\",\n      \"journal\": \"American journal of hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP evidence for histone acetylation at TIMP3 promoter with functional rescue; single lab\",\n      \"pmids\": [\"30715128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ALKBH5 (an m6A RNA demethylase) represses TIMP3 mRNA stability and protein production in non-small cell lung cancer. RIP-Seq identified TIMP3 mRNA as an ALKBH5-bound target; ALKBH5 knockdown increased TIMP3 expression and reduced tumor growth in vivo, establishing an ALKBH5-mediated m6A modification as a post-transcriptional regulator of TIMP3.\",\n      \"method\": \"RNA immunoprecipitation sequencing (RIP-Seq), ALKBH5 KD/OE, mRNA stability assay, Western blot, in vivo xenograft, RT-qPCR\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — RIP-Seq identifies direct binding, mRNA stability assay provides mechanistic link; single lab\",\n      \"pmids\": [\"31927006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LncRNA ROR recruits histone methyltransferase MLL1 to promote H3K4 trimethylation at the TIMP3 locus, enhancing TIMP3 transcription and breast cancer progression. RIP, RNA pull-down, and ChIP assays confirmed lncRNA ROR-MLL1-H3K4me3-TIMP3 axis; lncRNA ROR knockdown inhibited breast cancer cell invasion and tumor growth through downregulation of TIMP3.\",\n      \"method\": \"RIP assay, RNA pull-down, ChIP for H3K4me3 at TIMP3, lncRNA ROR KD/OE, Transwell invasion assay, in vivo xenograft\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct chromatin occupancy assay (ChIP) and RNA-protein interaction assays; single lab\",\n      \"pmids\": [\"33653378\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TIMP3 is an ECM-bound inhibitor with a broad substrate spectrum including MMPs, ADAM17/TACE, ADAMs, and ADAMTSs; it maintains vascular, renal, cardiac, and hepatic homeostasis primarily by restricting TACE-mediated TNF-alpha shedding and MMP-dependent ECM degradation, and it promotes endothelial apoptosis through a caspase-independent FAK-disruption mechanism, while its expression level is regulated by the CLOCK circadian factor, by epigenetic writers/erasers (KDM1A, HDAC9, MLL1, ALKBH5), and by numerous miRNAs targeting its long 3′UTR.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TIMP3 is an extracellular-matrix-bound metalloproteinase inhibitor that maintains vascular, renal, cardiac, hepatic, and metabolic homeostasis primarily by restraining the sheddase ADAM17/TACE and matrix metalloproteinases [#0, #3, #18]. Unlike other TIMPs, TIMP3 is sequestered exclusively in the ECM rather than secreted into the medium, accumulating in basement membranes near RPE and endothelial cells [#15]. A central function is direct inhibition of TACE, silencing TNF-alpha shedding: TACE exists as cell-surface dimers whose cytoplasmic-domain-dependent dimerization enables stable TIMP3 association, and MAPK-driven dimer-to-monomer conversion releases TIMP3 to permit ectodomain shedding [#1]. Through this TACE-TNF-alpha axis, TIMP3 limits inflammation and downstream MMP2 activation in renal injury, atherosclerosis, autoimmune hepatitis, and diabetic kidney disease, where loss of TIMP3 elevates TACE activity and engages a STAT1-FoxO1 autophagy pathway [#0, #3, #7, #19, #21]. TIMP3 also broadly restricts metalloproteolysis (MMP2, ADAMs, ADAMTSs) to stabilize the microvasculature and ECM: pericyte-derived, ALK5-induced TIMP3 maintains capillary integrity and prevents fibrosis, microvascular rarefaction, aneurysm, and germinal-matrix hemorrhage [#4, #6, #14]. Beyond protease inhibition, TIMP3 drives caspase-independent endothelial apoptosis requiring VEGFR2 (KDR) by blocking matrix-induced FAK phosphorylation and disrupting focal-adhesion assembly [#11]. TIMP3 expression is itself tightly controlled at multiple levels — by the circadian factor CLOCK [#25], by chromatin writers/erasers acting at its promoter (KDM1A, HDAC9, MLL1) [#27, #29, #31], and post-transcriptionally by the m6A demethylase ALKBH5 [#30]. The Sorsby fundus dystrophy S156C mutation does not impair TIMP3's inhibitory activities but causes pathological ECM accumulation that alters cellular morphology [#17, #18].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Defining the TIMP3 gene architecture and promoter established how its expression is set, including serum-inducible cell-cycle regulation, framing later studies of its transcriptional control.\",\n      \"evidence\": \"Genomic cloning, chromosomal mapping, and promoter-reporter deletion assays in growth-arrested cells\",\n      \"pmids\": [\"7487894\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the trans-acting factors mediating serum inducibility\", \"No link yet to protein function or substrate spectrum\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Showing that TIMP3, unlike TIMP-1/-2, is bound exclusively in the ECM and not the medium established its distinctive spatial mode of action as a matrix-tethered inhibitor.\",\n      \"evidence\": \"ECM-vs-medium fractionation, immunoblot, and IHC in RPE, pericytes, and endothelial cells\",\n      \"pmids\": [\"9068940\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of ECM retention not defined\", \"Functional consequence of matrix tethering not yet tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Testing the SFD S156C mutation addressed whether disease arises from loss of protease inhibition; it showed the mutant retains MMP-inhibitory activity but abnormally accumulates in ECM and alters cell morphology.\",\n      \"evidence\": \"MMP activity assays, ECM fractionation, and pulse-chase in S156C knock-in and Timp3-/- fibroblasts\",\n      \"pmids\": [\"12942551\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking ECM accumulation to morphology change unresolved\", \"Single lab; not extended to retinal phenotype in vivo\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Placing TIMP3 upstream of TACE-mediated TNF-alpha shedding answered how a protease inhibitor governs metabolic inflammation, linking TIMP3 loss to diabetes and vascular inflammation.\",\n      \"evidence\": \"Insr+/-, Timp3+/-, double-heterozygote mice with TACE activity assays and pharmacological TACE inhibition\",\n      \"pmids\": [\"16294222\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the structural basis of TIMP3-TACE binding\", \"Tissue-specific contributions not dissected\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Extending TIMP3 inhibition to ADAM-10/17 in APP processing and to cardiac remodeling broadened its substrate-spectrum and physiological reach to neuronal shedding and post-MI dysfunction.\",\n      \"evidence\": \"Recombinant TIMP3 with APP fragment/surface-biotinylation analysis (neural cells); Timp3-/- coronary ligation with echocardiography and zymography\",\n      \"pmids\": [\"17913923\", \"17945252\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"APP study single-lab, Medium confidence\", \"Direct contribution to human Alzheimer pathology not established\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Double-knockout epistasis established the TACE-TNF-alpha-MMP2 cascade as the mechanistic chain through which TIMP3 protects the injured kidney.\",\n      \"evidence\": \"TIMP3-/- and TIMP3-/-/TNFalpha-/- mice, ureteral obstruction, TACE assay, MMP zymography, MMP inhibitor\",\n      \"pmids\": [\"19406980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address why MMP2 but not MMP9 is selectively activated\", \"Cell-type source of protective TIMP3 not defined here\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Dissecting TACE dimerization revealed how TIMP3 inhibition is gated: TIMP3 silences only dimeric TACE, and MAPK-driven monomerization releases the inhibitor to permit shedding.\",\n      \"evidence\": \"Cell-surface dimerization assays, TIMP3-TACE co-IP, MAPK modulation, TGF-alpha shedding, cytoplasmic-domain mutagenesis\",\n      \"pmids\": [\"22550340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic structure of the dimer-TIMP3 complex not resolved\", \"In vivo relevance of dimer state not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"A series of in vivo models established TIMP3 as a tissue-protective regulator across microvascular stability, diabetic kidney injury, aortic aneurysm, and hepatic immune tolerance, often via TACE/MMP2 control.\",\n      \"evidence\": \"Pericyte 3D tube assays and Timp3-/- kidney injury; Timp3-/-/Akita diabetic mice; Timp3-/-/Mmp2-/- Ang II aneurysm with bone-marrow chimeras; Timp3-/- ConA hepatitis chimeras\",\n      \"pmids\": [\"22383695\", \"22896043\", \"23144462\", \"22323541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Organ-selective vulnerability (e.g., kidney vs heart in diabetes) not mechanistically explained\", \"Relative weighting of TACE vs MMP2 contributions varies by tissue\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Comparative knockouts and a STAT1-FoxO1 rescue defined divergent TIMP roles (TIMP3 protective, TIMP2 injurious) and a transcriptional autophagy arm downstream of TIMP3 in diabetic kidney disease.\",\n      \"evidence\": \"Timp2-/- vs Timp3-/- ureteral obstruction; diabetic Timp3-/- mice with TIMP3 re-expression, STAT1 knockdown, and human biopsy validation\",\n      \"pmids\": [\"23760282\", \"23401241\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How extracellular TIMP3 controls intracellular STAT1/FoxO1 not mechanistically connected\", \"TIMP2 opposing mechanism not fully resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Studies of cardiac fibrosis, atherosclerosis, and hepatocellular carcinoma revealed context-dependent outcomes of TIMP3 loss, including MMP-independent fibrosis, macrophage M1 polarization, and paradoxical tumor protection via senescence.\",\n      \"evidence\": \"Timp3-/- Ang II hearts with osteopontin/SPARC analysis; ApoE-/-/Timp3-/- atherosclerosis with FACS; Timp3-/- DEN hepatocarcinogenesis with p53/p38/Notch and TNF epistasis\",\n      \"pmids\": [\"24692173\", \"24943223\", \"25347747\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism switching TIMP3 between protective and tumor-promoting roles unresolved\", \"MMP-independent fibrotic mechanism only partially defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Establishing a caspase-independent, VEGFR2-dependent FAK-disruption mechanism showed TIMP3 drives endothelial apoptosis separately from its protease-inhibitory function.\",\n      \"evidence\": \"VEGFR2-expressing vs control cell lines, recombinant TIMP3, FAK phosphorylation, FAK/paxillin co-IP, caspase inhibition, in vivo tumor assay\",\n      \"pmids\": [\"25558000\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How matrix-bound TIMP3 transduces signal through VEGFR2 to FAK not defined\", \"Direct TIMP3-VEGFR2 binding interface not mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"CADASIL models identified excess TIMP3 as a direct, dose-dependent cause of cerebrovascular dysfunction through ADAM17/HB-EGF inhibition and KV channel upregulation, and a histone demethylase (KDM1A) was shown to silence TIMP3 to enable cancer metastasis.\",\n      \"evidence\": \"TgNotch3(R169C) and TgBAC-TIMP3 mice with Timp3 haploinsufficiency rescue, patch-clamp, ADAM17/HB-EGF treatment; KDM1A KD/OE with ChIP-qPCR for H3K4me2 and invasion assays\",\n      \"pmids\": [\"27476853\", \"26648042\", \"27058897\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"KDM1A regulation is Medium confidence, single lab\", \"How TIMP3 accumulates in CADASIL not fully explained\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Hepatocyte-specific TIMP3 gain and ADAM17 loss demonstrated cell-autonomous metabolic protection, placing TIMP3 upstream of hepatocyte ADAM17 in NAFLD, tumorigenesis, and iron handling.\",\n      \"evidence\": \"AlbT3, hepatocyte and myeloid Adam17 KO mice under HFD, DEN, and iron-overload models with metabolic and ferroportin/MMP readouts\",\n      \"pmids\": [\"28751722\", \"29373036\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which TIMP3 controls ferroportin not defined\", \"Iron-overload study Medium confidence, single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identifying TIMP3 as both an ALK5-induced effector in brain vascular morphogenesis and a CLOCK-dependent circadian gene linked its expression control to developmental signaling and diurnal rhythm.\",\n      \"evidence\": \"Pericyte-specific Alk5 conditional KO with in vivo TIMP3 rescue; CLOCK and TIMP3 KD/OE in UVB-treated keratinocytes\",\n      \"pmids\": [\"29456135\", \"29180440\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Circadian regulation Medium confidence, in vitro only\", \"Direct CLOCK occupancy at the TIMP3 locus not shown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Biochemical and epigenetic studies refined how TIMP3 activity and expression are tuned: glycosaminoglycans modulate MMP2/TIMP3 complex formation, while HDAC9 represses TIMP3 transcription in trophoblasts.\",\n      \"evidence\": \"MMP2/TIMP3 complex assays with sulfated hyaluronan/heparin and molecular dynamics; ChIP-qPCR for histone acetylation with HDAC9 knockdown/rescue and invasion assays\",\n      \"pmids\": [\"30894640\", \"30715128\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GAG study lacks mutagenesis validation\", \"HDAC9 axis single lab; preeclampsia causality not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Post-transcriptional and lncRNA-guided chromatin mechanisms (ALKBH5 m6A demethylation and lncRNA ROR-MLL1-H3K4me3) were shown to control TIMP3 levels in cancer, expanding its regulatory layers.\",\n      \"evidence\": \"RIP-Seq, mRNA stability assays, and xenografts for ALKBH5; RIP, RNA pull-down, ChIP, and xenografts for lncRNA ROR-MLL1\",\n      \"pmids\": [\"31927006\", \"33653378\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Both single-lab studies\", \"Specific m6A sites and their functional weight not mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How matrix-tethered, extracellular TIMP3 transmits signals to intracellular effectors (STAT1/FoxO1, FAK, VEGFR2) and what governs its context-dependent switch between tissue protection and tumor promotion remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of TIMP3 engaging cell-surface receptors\", \"Mechanism integrating its protease-inhibitory and protease-independent functions unclear\", \"Determinants of opposing roles across tissues undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 3, 18]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 2, 18]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [15, 17]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [4, 6, 9, 26]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 3, 19, 21]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [11, 20, 22]},\n      {\"term_id\": \"R-HSA-9909396\", \"supporting_discovery_ids\": [25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ADAM17\", \"ADAM10\", \"MMP2\", \"KDR\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}